CN105748516A - Pharmaceutical composition for treating repeated oral ulcers - Google Patents
Pharmaceutical composition for treating repeated oral ulcers Download PDFInfo
- Publication number
- CN105748516A CN105748516A CN201610193397.XA CN201610193397A CN105748516A CN 105748516 A CN105748516 A CN 105748516A CN 201610193397 A CN201610193397 A CN 201610193397A CN 105748516 A CN105748516 A CN 105748516A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- liquid
- oral
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of oral ulcer treatment medicine, in particular to a pharmaceutical composition for treating repeated oral ulcers.The pharmaceutical composition is prepared from, by weight, 5-8 parts of zinc gluconate oral liquid, 15-20 parts of vitamin B2, 10-15 parts of whole milk powder, 3-5 parts of iodine glycerol, 5-8 parts of levamisole, 0.5-1 part of dyclonine liquid and 0.5-1 part of dicaine liquid.Compared with the prior art, the pharmaceutical composition has the advantages that all drugs act cooperatively and have the effects of supplementing zinc, vitamin B2, iron, phosphorus and the like, so that self immunity is improved, cell regeneration is promoted, elimination of inflammations in the oral cavity, lips and tongue is assisted, and oral cavity epidermis healing is promoted; thorough treatment of repeated oral ulcers is realized, and no toxic or side effect is caused.
Description
Technical field
The present invention relates to Aphthasol thing technical field, particularly to a kind of pharmaceutical composition treating repeatability oral ulcer.
Background technology
Oral ulcer is also called " aphtha ", is to occur at the ulcer on oral mucosa, is apt to occur in lip, cheek, lingual margin etc., big I from the grain of rice to Semen Glycines size, circular or oval, ulcer surface is recessed, congested around, can cause pain because of irritable food, and generally one or two week can spontaneous recovery.Oral ulcer inducement is probably local wound, psychentonia, food, medicine, hormonal readiness change and vitamin or trace element deficiency etc., and another common cold, dyspepsia, psychentonia, the gloomy situation such as discomfort all can accidentally cause the generation of this disease.Recurrent oral ulceration is the one of oral ulcer disease, is exactly outbreak repeatedly as its name, has periodically, the feature such as recurrent and self limiting, and the effect treated very bad.
A lot of people are suffering from oral ulcer, so having oneself conventional Therapeutic Method for this sick most people, it is common that the medicine of external point anti-inflammatory type, or take vitamin B2, vitamin C etc..But these treatments are only capable of improving symptom, can not control the recurrent exerbation of oral ulcer.
Summary of the invention
Present invention aims to the defect of prior art and deficiency, it is provided that a kind of pharmaceutical composition treating repeatability oral ulcer.
For achieving the above object, the technical solution used in the present invention is:
A kind of pharmaceutical composition treating repeatability oral ulcer of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution 5～8 parts, vitamin B215～20 parts, whole milk powder 10～15 parts, iodine glycerol 3～5 parts, levamisole 5～8 parts, dyclonine liquid 0.5～1 part, tetracaine liquid 0.5～1 part.
Further, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 5 parts, vitamin B2Being 20 parts, whole milk powder is 10 parts, and iodine glycerol is 3 parts, and levamisole is 5 parts, and dyclonine liquid is 0.5 part, and tetracaine liquid is 1 part.
Further, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 7 parts, vitamin B2Being 15 parts, whole milk powder is 13 parts, and iodine glycerol is 5 parts, and levamisole is 8 parts, and dyclonine liquid is 0.8 part, and tetracaine liquid is 0.8 part.
Further, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 8 parts, vitamin B2Being 17 parts, whole milk powder is 15 parts, and iodine glycerol is 4 parts, and levamisole is 7 parts, and dyclonine liquid is 1 part, and tetracaine liquid is 0.5 part.
The present invention compared with prior art provides the benefit that: by by Zinc Gluuconate Oral Solution, vitamin B2, whole milk powder, iodine glycerol, levamisole, dyclonine liquid become medicament, various drug synergisms with tetracaine liquid mixing manufacture, there is zinc supplement, mend vitamin B2, iron supplement, the effect such as phosphorus supplement, and then improve immunity voluntarily, promote the regeneration of cell, help to eliminate in oral cavity, the inflammation of lip, tongue, promote oral cavity epidermis to heal；Realize thoroughly treating the oral ulcer of recurrent exerbation, and have no side effect.
Detailed description of the invention
Describing the present invention below in conjunction with specific embodiment, following embodiment and explanation are only used for explaining the present invention, but not as a limitation of the invention.
A kind of pharmaceutical composition treating repeatability oral ulcer of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution 5～8 parts, vitamin B215～20 parts, whole milk powder 10～15 parts, iodine glycerol 3～5 parts, levamisole 5～8 parts, dyclonine liquid 0.5～1 part, tetracaine liquid 0.5～1 part.Levamisole can be used for strengthening immunization of cell；Dyclonine liquid and tetracaine liquid can play temporary transient pain relieving, allow skin loosen, it is simple to medicine effectively absorbs, it is to avoid ulcer place produces secondary insult when meeting medicine, and then improves therapeutic effect.
As first example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 5 parts, vitamin B2Being 20 parts, whole milk powder is 10 parts, and iodine glycerol is 3 parts, and levamisole is 5 parts, and dyclonine liquid is 0.5 part, and tetracaine liquid is 1 part, and every part is 1 gram.
As second example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 7 parts, vitamin B2Being 15 parts, whole milk powder is 13 parts, and iodine glycerol is 5 parts, and levamisole is 8 parts, and dyclonine liquid is 0.8 part, and tetracaine liquid is 0.8 part, and every part is 1 gram.
As the 3rd example of the present invention, described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 8 parts, vitamin B2Being 17 parts, whole milk powder is 15 parts, and iodine glycerol is 4 parts, and levamisole is 7 parts, and dyclonine liquid is 1 part, and tetracaine liquid is 0.5 part, and every part is 1 gram.
The preparation method of the present invention, by Zinc Gluuconate Oral Solution, vitamin B2, whole milk powder, iodine glycerol, levamisole, dyclonine liquid and tetracaine liquid mix homogeneously, and utilize prior art to make spray, after rinsing the mouth, be sprayed on ulcer place, spray 5～6 every day.
Treatment analysis of cases:
The spray using the formula of above-mentioned three kinds of examples to make, chooses 400 examples and suffers from the patient of repeatability oral ulcer, is all from outpatient service, 18～65 years old age, the course of disease 6 months～34 years；Recurrence period is 15 days～3 months, and ulcer number is general simultaneously more than 2.Above case is randomly divided into first group, second group, the 3rd group and matched group four groups, and first group is 100 examples, 45 years old mean age；Second group is 100 examples, 48 years old mean age；3rd group is 100 examples, 40 years old mean age；Matched group 100 example, 44.5 years old mean age.
Diagnostic criteria: from the beginning of one or more small red dot or phlysis occur on oral mucosa, rear diabrosis, form Semen phaseoli radiati or the big aphtha of Semen Glycines.Ulcer is rounded or oval, and its surface is many yellow-white pseudomembrane again, around around with blush.
First group: make spray by the first Exemplary drugs compositions, after rinsing the mouth, be sprayed on ulcer place, spray 5～6 every day.The thing avoided pungent food.Serveing on 5 days is a course for the treatment of.
Second group: make spray by the second Exemplary drugs compositions, after rinsing the mouth, be sprayed on ulcer place, spray 5～6 every day.The thing avoided pungent food.Serveing on 5 days is a course for the treatment of.
3rd group: make spray by the 3rd Exemplary drugs compositions, after rinsing the mouth, it is sprayed on ulcer place, sprays 5～6 every day.The thing avoided pungent food.Serveing on 5 days is a course for the treatment of.
Matched group: take mouth ulcer lozenge, oral vitamin B2Treatment, the thing avoided pungent food.Every day 3 times, 5 days is a course for the treatment of.
Criterion of therapeutical effect: recovery from illness: oral ulcer recovery from illness after the course for the treatment of, tracing study more than 3 months is without recurrence.Effective: the recurrence period of oral ulcer significantly extends, within more than 3 months, to be recurred once by successively or being monthly repeatedly extended down to, and after recurrence, symptom substantially alleviates, the spontaneous recovery time shortens to 3～5 days.Effective: the recurrence period of oral ulcer significantly extends, within more than 1 month, recurred once by successively or being monthly repeatedly extended down to.Invalid: after the course for the treatment of, symptom is not improved.
Therapeutic outcome is table as above: the first to three group is respectively compared with matched group, and difference has significant, and prompting the first to three group curative effect is better than matched group.
The present invention compared with prior art provides the benefit that: by by Zinc Gluuconate Oral Solution, vitamin B2, whole milk powder, iodine glycerol, levamisole, dyclonine liquid become medicament, various drug synergisms with tetracaine liquid mixing manufacture, there is zinc supplement, mend vitamin B2, iron supplement, the effect such as phosphorus supplement, and then improve immunity voluntarily, promote the regeneration of cell, help to eliminate in oral cavity, the inflammation of lip, tongue, promote oral cavity epidermis to heal；Realize thoroughly treating the oral ulcer of recurrent exerbation, and have no side effect.
The above is only in order to conveniently to illustrate the present invention, and in the scope created without departing from the present invention, that is familiar with that those skilled in the art of this technology does various simple covert should belong to protection scope of the present invention with modifying.
Claims (4)
1. the pharmaceutical composition treating repeatability oral ulcer, it is characterised in that: described pharmaceutical composition is made up of each component of following weight proportioning:
Zinc Gluuconate Oral Solution 5～8 parts,
Vitamin B215～20 parts,
Whole milk powder 10～15 parts,
Iodine glycerol 3～5 parts,
Levamisole 5～8 parts,
Dyclonine liquid 0.5～1 part,
Tetracaine liquid 0.5～1 part.
2. a kind of pharmaceutical composition treating repeatability oral ulcer according to claim 1, it is characterised in that: described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 5 parts, vitamin B2Being 20 parts, whole milk powder is 10 parts, and iodine glycerol is 3 parts, and levamisole is 5 parts, and dyclonine liquid is 0.5 part, and tetracaine liquid is 1 part.
3. a kind of pharmaceutical composition treating repeatability oral ulcer according to claim 1, it is characterised in that: described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 7 parts, vitamin B2Being 15 parts, whole milk powder is 13 parts, and iodine glycerol is 5 parts, and levamisole is 8 parts, and dyclonine liquid is 0.8 part, and tetracaine liquid is 0.8 part.
4. a kind of pharmaceutical composition treating repeatability oral ulcer according to claim 1, it is characterised in that: described pharmaceutical composition is made up of each component of following weight proportioning: Zinc Gluuconate Oral Solution is 8 parts, vitamin B2Being 17 parts, whole milk powder is 15 parts, and iodine glycerol is 4 parts, and levamisole is 7 parts, and dyclonine liquid is 1 part, and tetracaine liquid is 0.5 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610193397.XA CN105748516A (en) | 2016-03-30 | 2016-03-30 | Pharmaceutical composition for treating repeated oral ulcers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610193397.XA CN105748516A (en) | 2016-03-30 | 2016-03-30 | Pharmaceutical composition for treating repeated oral ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105748516A true CN105748516A (en) | 2016-07-13 |
Family
ID=56345496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610193397.XA Pending CN105748516A (en) | 2016-03-30 | 2016-03-30 | Pharmaceutical composition for treating repeated oral ulcers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105748516A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650861A (en) * | 2004-11-30 | 2005-08-10 | 何岚峰 | Medicinal solution for treating ulceration and inflammation |
| CN101468039A (en) * | 2007-12-24 | 2009-07-01 | 赵呈利 | Method for preparing compound double-layer sustained-release medicinal membrane for treating oral mucosal disease |
| CN102552734A (en) * | 2012-02-29 | 2012-07-11 | 山西医科大学 | Gargle for treating dental ulcer |
-
2016
- 2016-03-30 CN CN201610193397.XA patent/CN105748516A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650861A (en) * | 2004-11-30 | 2005-08-10 | 何岚峰 | Medicinal solution for treating ulceration and inflammation |
| CN101468039A (en) * | 2007-12-24 | 2009-07-01 | 赵呈利 | Method for preparing compound double-layer sustained-release medicinal membrane for treating oral mucosal disease |
| CN102552734A (en) * | 2012-02-29 | 2012-07-11 | 山西医科大学 | Gargle for treating dental ulcer |
Non-Patent Citations (1)
| Title |
|---|
| 国家食品药品监督管理局执业药师资格认证中心组织编写: "口腔溃疡", 《药学综合知识与技能》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230346869A1 (en) | Formulation for management of post-oral surgical recovery and maintenance of oral health | |
| JP7096332B2 (en) | Compositions for use in the prevention and / or treatment of tumor treatment-induced oral gastrointestinal mucositis | |
| US20210128514A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
| CN110787202A (en) | Wind-dispelling and collateral-activating oil | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| Razikova | The condition of tissues in the oral cavity of patients with complications of arterial hypertension COVID-19 | |
| JP2000512270A (en) | Compositions and methods for the treatment of herpes simplex | |
| CN105748516A (en) | Pharmaceutical composition for treating repeated oral ulcers | |
| US20130243702A1 (en) | Mouthwash Composition for Managing Oral Mucositis, Process and Methods Thereof | |
| CN102552734B (en) | Gargle for treating dental ulcer | |
| WO2003061676A1 (en) | Compositions for and method of treatment for skin ailments | |
| KR20160102669A (en) | Composition for preventing or treating of Henoch-Schonlein Purpura | |
| RU2362575C1 (en) | Homeopathic compositions of doctor kosmodemjansky for treatment and prevention of respiratory inflammatory diseases and their complications, and also ways of their application | |
| JP4221266B2 (en) | Drugs for suppressing or alleviating symptoms of allergic diseases | |
| RU2772293C1 (en) | Method for treatment of chronic aphthous stomatitis | |
| KR101548254B1 (en) | Composition for treating skin disease comprising sulfur, alum and vinegar | |
| CN102670713A (en) | Traditional Chinese medicine for treating oral ulcers | |
| RU2705162C1 (en) | Ointment for treating psoriasis (versions) | |
| CN101632762A (en) | Traditional Chinese medicine ointment for treating child aphtha | |
| CN1108537A (en) | Housewife dermatitis treatment | |
| CN114796176A (en) | A pharmaceutical composition for treating dermatoses, and its preparation method | |
| Doyle et al. | Use of milontin in the treatment of petit mal epilepsy (three per second spike and wave dysrhythmia) | |
| Sutaria et al. | Management of Uttana vatarakta (limited cutaneous systemic sclerosis): An experience through Ayurveda management strategies | |
| CN103877151A (en) | Egg butter traditional Chinese medicine ointment for treating oral ulcer | |
| CN105030983A (en) | External use traditional Chinese medicine for treating eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160713 |